https://www.journalofclinicalpathways.com/article/covid-19-pandemic-vindicates-ispor-value-flower
COVID-19 Pandemic Vindicates the ISPOR Value Flower
Authored by
Jason Shafrin, PhD; Kathy Lang, PhD; Ross Maclean, MD
Disclosures
In addition to noting employment by PRECISIONheor, Drs Shafrin, Lang, and Maclean report that they own stock in Precision Medicine Group.
Citation
J Clin Pathways. 2020;6(5):53-56. doi:10.25270/jcp.2020.6.00002
Received May 18, 2020; accepted June 4, 2020.
Correspondence
Jason Shafrin, PhD
11100 Santa Monica Blvd., Suite 500
Los Angeles, CA 90025
Phone: (310) 984-7705
Email: jason.shafrin@precisionvh.com
Abstract: What is the right price for a new treatment for COVID-19? One common approach—which is frequently used worldwide and in the United States by the Institute of Clinical and Economic Review—measures treatment value based largely on quality-adjusted life years (QALYs) gained by patients’ net of cost. In the case of COVID-19, however, it is clear that a new vaccine or treatment would be valued by society much more than simply average QALYs gained to patients who contracted the disease. In this commentary, the authors argue that the International Society for Pharmacoeconomics and Outcomes Research “value flower” provides a helpful framework to more accurately value treatments—such as those for COVID-19—which have a transformational impact on the lives of not only of patients, but also caregivers, employers, and broader society.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.